120 results
Page 4 of 6
6-K
EX-99.1
fsgcsqtw
5 Mar 21
ObsEva Announces Year End 2020 Financial Results
7:21am
6-K
EX-99.1
kuynct
10 Feb 21
ObsEva Provides Business Outlook for 2021
6:10am
6-K
EX-99.1
8f3skfl sk
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K
EX-99.1
io0380ab03okvuyu1
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
6-K
EX-99.1
qol616 jaw9ngqbos
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
lnvlfo3s9 fa2ar7jtu9
24 Nov 20
Current report (foreign)
6:03am
6-K
EX-99.1
ip4yiysp8bu63xwds
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-99.1
97osyk49gjvsltuam
9 Nov 20
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
7:32am
6-K
EX-1.1
g2ccue3zx8vq30
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
EX-99.1
4h65dszc7
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
xcarp015nk3u
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
EX-99.3
j049d7
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.1
zpn v0aa3nj6
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
EX-99.1
jprvv2pt t0yy
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
EX-99.1
ib0pvn7chv o3
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
EX-99.3
2d0qprvj
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
pl4uumt uuj435lvje4o
23 Mar 20
ObsEva Provides Update Related to COVID-19 Pandemic
4:00pm